491 results
8-K
EX-99.1
APTO
Aptose Biosciences Inc
26 Mar 24
Aptose Reports Results for the Fourth Quarter and Full Year 2023
4:04pm
planned Company operations including research and development through August of 2024.
Working capital is a non-GAAP measure and represents cash, cash … party
Research and development expenses
General and administrative expenses
Net finance income
Net loss
Basic and diluted loss per Common Share
424B4
APTO
Aptose Biosciences Inc
26 Jan 24
Prospectus supplement with pricing info
5:30pm
and licensees pursue clinical trials and research and development efforts. To become profitable, we, either alone or with our collaborators and licensees, must … considered to be in the development stage. The continuation of our research and development activities and the commercialization of the targeted
8-K
EX-99.1
fgh3ga15
9 Nov 23
Aptose Reports Results for the Third Quarter 2023
4:15pm
8-K
EX-99.1
r2dz4ye
10 Aug 23
Aptose Reports Results for the Second Quarter 2023
4:10pm
8-K
EX-99.1
fkz 1s0had8k
8 May 23
Aptose Reports Results for the First Quarter 2023
4:05pm
424B5
m6t2jzdj7osxh
9 Dec 22
Prospectus supplement for primary offering
6:59pm
8-K
EX-99.1
c7jhc57qah3tbj8nf
1 Nov 22
Aptose Reports Results for the Third Quarter 2022
4:01pm
424B2
apgx5g 7v022sq
21 Oct 22
Prospectus for primary offering
5:15pm